"Octreotide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
| Descriptor ID |
D015282
|
| MeSH Number(s) |
D04.345.566.650 D12.644.641.650
|
| Concept/Terms |
SMS 201-995- SMS 201-995
- SMS 201 995
- SMS 201995
- SM 201-995
- SM 201 995
- SM 201995
- Sandoz 201-995
- Sandoz 201 995
- Sandoz 201995
- Compound 201-995
- Compound 201 995
- Compound 201995
- SAN 201-995
- SAN 201 995
- SAN 201995
|
Below are MeSH descriptors whose meaning is more general than "Octreotide".
Below are MeSH descriptors whose meaning is more specific than "Octreotide".
This graph shows the total number of publications written about "Octreotide" by people in this website by year, and whether "Octreotide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octreotide" by people in Profiles.
-
Samson SL, Nachtigall LB, Fleseriu M, Jensterle M, Manning PJ, Elenkova A, Molitch ME, Ludlam WH, Patou G, Haviv A, Biermasz NR, Giustina A, Strasburger CJ, Kennedy L, Melmed S. Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur J Endocrinol. 2022 Dec 01; 187(6):733-741.
-
Daniels LM, Khalili M, Morano WF, Simoncini M, Mapow BC, Leaf A, Bowne WB. Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up. World J Surg Oncol. 2019 Dec 09; 17(1):213.
-
White SC, Seckeler MD, McCulloch MA, Buck ML, Hoke TR, Haizlip JA. Patients with single ventricle anatomy may respond better to octreotide therapy for chylothorax after congenital heart surgery. J Card Surg. 2014 Mar; 29(2):259-64.
-
Valsecchi ME, Coronel M, Intenzo CM, Kim SM, Witkiewicz AK, Sato T. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res. 2013 Feb; 23(1):33-9.
-
Sass DA, Chopra KB. Portal hypertension and variceal hemorrhage. Med Clin North Am. 2009 Jul; 93(4):837-53, vii-viii.
-
Fasano CJ, Rowden AK. Successful treatment of repaglinide-induced hypoglycemia with octreotide. Am J Emerg Med. 2009 Jul; 27(6):756.e3-4.
-
Fasano CJ, O'Malley G, Dominici P, Aguilera E, Latta DR. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2008 Apr; 51(4):400-6.
-
Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot. 2002 Nov; 57(5):749-63.
-
Rao PS, Thakur ML, Pallela V, Patti R, Reddy K, Li H, Sharma S, Pham HL, Diggles L, Minami C, Marcus CS. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol. 2001 May; 28(4):445-50.
-
Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3.